Business Context and Reporting Period
This Form 8-K Current Report was filed by BiomX Inc. (PHGE) on June 2, 2026. The filing discloses unregistered sales of equity securities and the establishment of a new credit facility.
Key Financial Metrics and Capital Structure
- Equity Issuance: 1,013,637 restricted shares of common stock issued on June 2, 2026.
- Debt Conversion: Shares issued upon partial conversion of approximately $379,000 in principal from a convertible promissory note.
- Outstanding Shares: Total common stock issued and outstanding is now 11,160,153 shares.
- Debt Facility: A revolving line of credit of up to $2,000,000 established on May 13, 2026, with Mandragola Ltd.
- Interest Rate: Advances under the credit line bear simple annual interest at 12%.
- Warrant Issuance: A five-year warrant issued to purchase up to 2,000,000 shares at an exercise price of $12.00 per share (includes cashless exercise feature).
Material Changes
The primary material change is the increase in outstanding share count due to the conversion of debt held by Mandragola Ltd. Additionally, the company has secured a new $2,000,000 revolving credit line, which includes the reclassification of prior advances related to the acquisition of a controlling stake in Dr. Frucht Systems Ltd. (DFSL) as part of this new facility.
Outlook, Risks, and Contingencies
- Regulatory Requirement: The shares issuable upon exercise of the warrant are subject to obtaining stockholder approval under NYSE American rules.
- Exemption Reliance: Both the conversion shares and the warrant were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, meaning they were not registered and no general solicitation was used.
- Conversion Terms: Future conversions of the credit line notes will be based on the closing price of the common stock on the trading day immediately preceding the delivery of the conversion notice.
Investor Verification Checklist
- Verify the exact conversion price per share for the 1,013,637 shares issued (derived from the $379,000 principal).
- Confirm the status of stockholder approval required for the 2,000,000 share warrant exercise.
- Review the full Line of Credit Agreement (Exhibit 10.1) for covenants, default provisions, and repayment terms.
- Assess the dilution impact of the warrant and potential future note conversions on existing shareholders.
- Check for any subsequent filings regarding the utilization of the $2,000,000 credit line.